Unknown

Dataset Information

0

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.


ABSTRACT: Inhibition of NS5A has emerged as an attractive strategy to intervene in hepatitis C virus (HCV) replication. Ruzasvir (formerly MK-8408) was developed as a novel NS5A inhibitor to improve upon the potency and barrier to resistance of early compounds. Ruzasvir inhibited HCV RNA replication with 50% effective concentrations (EC50s) of 1 to 4 pM in Huh7 or Huh7.5 cells bearing replicons for HCV genotype 1 (GT1) to GT7. The antiviral activity was modestly (10-fold) reduced in the presence of 40% normal human serum. The picomolar potency in replicon cells extended to sequences of clinical isolates available in public databases that were synthesized and tested as replicons. In GT1a, ruzasvir inhibited common NS5A resistance-associated substitutions (RASs), with the exception of M28G. De novo resistance selection studies identified pathways with certain amino acid substitutions at residues 28, 30, 31, and 93 across genotypes. Substitutions at position 93 were more common in GT1 to -4, while changes at position 31 emerged frequently in GT5 and -6. With the exception of GT4, the reintroduction of selected RASs conferred a ?100-fold potency reduction in the antiviral activity of ruzasvir. Common RASs from other classes of direct-acting antiviral agents (DAAs) did not confer cross-resistance to ruzasvir. The interaction of ruzasvir with an NS3/4A protease inhibitor (grazoprevir) and an NS5B polymerase prodrug (uprifosbuvir) was additive to synergistic, with no evidence of antagonism or cytotoxicity. The antiviral profile of ruzasvir supported its further evaluation in human trials in combination with grazoprevir and uprifosbuvir.

SUBMITTER: Asante-Appiah E 

PROVIDER: S-EPMC6201069 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>In Vitro</i> Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.

Asante-Appiah Ernest E   Liu Rong R   Curry Stephanie S   McMonagle Patricia P   Agrawal Sony S   Carr Donna D   Rokosz Laura L   Lahser Frederick F   Bystol Karin K   Chase Robert R   Black Stuart S   Ferrari Eric E   Ingravallo Paul P   Tong Ling L   Yu Wensheng W   Kozlowski Joseph J  

Antimicrobial agents and chemotherapy 20181024 11


Inhibition of NS5A has emerged as an attractive strategy to intervene in hepatitis C virus (HCV) replication. Ruzasvir (formerly MK-8408) was developed as a novel NS5A inhibitor to improve upon the potency and barrier to resistance of early compounds. Ruzasvir inhibited HCV RNA replication with 50% effective concentrations (EC<sub>50</sub>s) of 1 to 4 pM in Huh7 or Huh7.5 cells bearing replicons for HCV genotype 1 (GT1) to GT7. The antiviral activity was modestly (10-fold) reduced in the presenc  ...[more]

Similar Datasets

| S-EPMC4775926 | biostudies-literature
| S-EPMC5404558 | biostudies-literature
| S-EPMC4335823 | biostudies-literature
| S-EPMC4136001 | biostudies-literature
| S-EPMC2663092 | biostudies-literature
| S-EPMC5038316 | biostudies-literature
| S-EPMC5038307 | biostudies-literature
| S-EPMC4027583 | biostudies-literature
| S-EPMC3256078 | biostudies-literature
| S-EPMC5740381 | biostudies-literature